BioMimetic (BMTI) Receives FDA Panel Backing For Augment Bone Graft

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced late Thursday that the FDA Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee voted 12-6 in support of the safety of Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures. The panel also voted 10-8 in support of the efficacy of Augment for use as an alternative to autograft in hindfoot and ankle fusions. Additionally, the panel voted 10-8 that Augment demonstrates a favorable benefit to risk profile for the same indication.

Share of BioMimetic should resume trading shortly after being halted all day yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Two Binance Employees Detained In The U.A.E. Amid Police Inquiries - NYT
• Holcim said to acquire part of James Hardie's EU business